SARS‐CoV ‐2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad

Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis

(2020) Jieyun Zhu et al.   JOURNAL OF MEDICAL VIROLOGY

COVID-19: consider cytokine storm syndromes and immunosuppression

(2020) Puja Mehta et al.   LANCET

Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic

(2020) Lorenzo D’Antiga   LIVER TRANSPLANTATION

Two X‐linked agammaglobulinemia patients develop pneumonia as COVID‐19 manifestation but recover

(2020) Annarosa Soresina et al.   PEDIATRIC ALLERGY AND IMMUNOLOGY

COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

(2020) Giovanni Novi et al.   Multiple Sclerosis and Related Disorders

Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation

(2017) Katja Thomas et al.   Journal of Neuroinflammation

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

(2017) David Baker et al.   JAMA Neurology

Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment

(2017) David Baker et al.   Multiple Sclerosis and Related Disorders

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

(2017) David Baker et al.   EBioMedicine

Extended interval dosing of natalizumab in multiple sclerosis

(2016) L Zhovtis Ryerson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab

(2016) Yara Dadalti Fragoso et al.   Multiple Sclerosis and Related Disorders